Literature DB >> 17242859

Levetiracetam in three cases of progressive myoclonus epilepsy.

Savvas Papacostas1, Elena Kkolou, Eleftherios Papathanasiou.   

Abstract

We present three unrelated cases of genetically confirmed progressive myoclonic epilepsy of the Unverricht-Lundborg type who were treated with Levetiracetam as adjunctive therapy for their myoclonus. All cases responded with decrease of their myoclonus and improvement of quality of life. Two were able to return to or continue their employment. Patients tolerated the drug well without side effects reported. Levetiracetam appears to be a useful antimyoclonic agent in cases of progressive myoclonic epilepsy and should be considered for adjunctive therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17242859     DOI: 10.1007/s11096-006-9039-1

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  10 in total

1.  Efficacy of levetiracetam in a patient with Unverricht-Lundborg progressive myoclonic epilepsy.

Authors:  P Kinrions; N Ibrahim; K Murphy; A-E Lehesjoki; I Järvela; N Delanty
Journal:  Neurology       Date:  2003-04-22       Impact factor: 9.910

2.  Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices.

Authors:  I Niespodziany; H Klitgaard; D G Margineanu
Journal:  Neurosci Lett       Date:  2001-06-22       Impact factor: 3.046

3.  Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group.

Authors:  E Ben-Menachem; U Falter
Journal:  Epilepsia       Date:  2000-10       Impact factor: 5.864

4.  Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam.

Authors:  P Genton; P Gelisse
Journal:  Neurology       Date:  2001-09-25       Impact factor: 9.910

Review 5.  Levetiracetam: preliminary efficacy in generalized seizures.

Authors:  Dorothée G A Kasteleijn-Nolst Trenité; Edouard Hirsch
Journal:  Epileptic Disord       Date:  2003-05       Impact factor: 1.819

6.  Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations.

Authors:  Adriana Magaudda; Philippe Gelisse; Pierre Genton
Journal:  Epilepsia       Date:  2004-06       Impact factor: 5.864

7.  Mutations in the gene encoding cystatin B in progressive myoclonus epilepsy (EPM1)

Authors:  L A Pennacchio; A E Lehesjoki; N E Stone; V L Willour; K Virtaneva; J Miao; E D'Amato; L Ramirez; M Faham; M Koskiniemi; J A Warrington; R Norio; A de la Chapelle; D R Cox; R M Myers
Journal:  Science       Date:  1996-03-22       Impact factor: 47.728

8.  The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents.

Authors:  J-M Rigo; G Hans; L Nguyen; V Rocher; S Belachew; B Malgrange; P Leprince; G Moonen; I Selak; A Matagne; H Klitgaard
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

9.  The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.

Authors:  Berkley A Lynch; Nathalie Lambeng; Karl Nocka; Patricia Kensel-Hammes; Sandra M Bajjalieh; Alain Matagne; Bruno Fuks
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

10.  Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients.

Authors:  C Crest; S Dupont; E Leguern; C Adam; M Baulac
Journal:  Neurology       Date:  2004-02-24       Impact factor: 9.910

  10 in total
  3 in total

Review 1.  Update on Pharmacological Treatment of Progressive Myoclonus Epilepsies.

Authors:  Edoardo Ferlazzo; Dorothee Kasteleijn-Nolst Trenite; Gerrit-Jan de Haan; Felix Felix Nitschke; Saija Ahonen; Sara Gasparini; Berge A Minassian
Journal:  Curr Pharm Des       Date:  2017       Impact factor: 3.116

2.  Myoclonus.

Authors:  Victoria C Chang; Steven J Frucht
Journal:  Curr Treat Options Neurol       Date:  2008-05       Impact factor: 3.598

3.  Levetiracetam in the treatment of epilepsy.

Authors:  Bassel Abou-Khalil
Journal:  Neuropsychiatr Dis Treat       Date:  2008-06       Impact factor: 2.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.